11/18
08:35 am
artl
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit [Yahoo! Finance]
High
Report
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit [Yahoo! Finance]
11/18
08:30 am
artl
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
High
Report
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
11/13
08:30 am
artl
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
High
Report
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
11/13
08:05 am
artl
Artelo Biosciences, Inc. (NASDAQ: ARTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Artelo Biosciences, Inc. (NASDAQ: ARTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
11/12
08:00 am
artl
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Low
Report
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
11/5
08:30 am
artl
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
High
Report
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
10/9
09:00 am
artl
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
Low
Report
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
10/3
05:53 am
artl
Artelo Biosciences, Inc. (NASDAQ: ARTL) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Low
Report
Artelo Biosciences, Inc. (NASDAQ: ARTL) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
9/4
09:00 am
artl
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference